Synthetic peptide vaccine against Taenia solium pig cysticercosis:: successful vaccination in a controlled field trial in rural Mexico
Synthetic peptide vaccine against Taenia solium pig cysticercosis:: successful vaccination in a controlled field trial in rural Mexico
复制标题
DOI：
10.1016/s0264-410x(01)00249-3
复制
发表时间：
2001-10-12
期刊：
影响因子：
5.5
通讯作者：
Sciutto, E
中科院分区：
文献类型：
--
作者：
Huerta, M;de Aluja, AS;Sciutto, E
猪带绦虫囊尾蚴病发生在中枢神经系统（CNS）时，严重影响人类健康，给流行国家农村地区的养猪业造成巨大经济损失。提高强制宿主猪对寄生虫的抵抗力可能有助于遏制传播。三种基于鼠寄生虫粗头带绦虫蛋白质序列的合成肽已被证明可以诱导小鼠免受同源攻击的保护，并在猪中测试了其作为猪猪囊尾蚴病的疫苗。将接种疫苗和未接种疫苗的仔猪（共 240 头）成对分发到墨西哥两个乡村的农户中，其中 14% 的本地猪患有囊尾蚴病。十到十二个月后，在尸检时评估疫苗接种的效果。疫苗接种减少了猪囊尾蚴的总数（98.7%）并降低了患病率（52.6%）。该现场试验中使用的自然挑战条件增强了通过大规模猪疫苗接种计划成功控制猪和人类传播的可能性。我们相信这是抗囊尾蚴病疫苗开发的重大贡献，因为与更复杂的抗原相比，这些相当简单但具有保护性的肽的生产可能更具成本效益，并且结果的变化更小。 (C) 2001 Elsevier Science Ltd. 保留所有权利。
Taenia solium cysticercosis seriously affects human health when localised in the central nervous system (CNS) and causes great economic loss in pig husbandry in rural areas of endemic countries. Increasing the resistance to the parasite in the obligatory host pig may help in curbing transmission. Three synthetic peptides based on protein sequences of the murine parasite Taenia crassiceps, which had previously been shown to induce protection in mice against homologous challenge, were tested as a vaccine against T solium cysticercosis in pigs. Vaccinated and unvaccinated piglets (240 in all) were distributed in pairs among the peasants' households of two rural villages in Mexico in which 14% of the native pigs were cysticercotic. Ten to twelve months later, the effect of vaccination was evaluated at necropsy. Vaccination decreased the total number of T solium cysticerci (98.7%) and reduced the prevalence (52.6%). The natural challenge conditions used in this field trial strengthen the likelihood of successful transmission control to both pig and human through a large-scale pig vaccination program. We believe this is a major contribution in anticysticercosis vaccine development as these rather simple yet protective peptides are potentially more cost-effective to produce and less variable in results than antigens that are more complex. (C) 2001 Elsevier Science Ltd. All rights reserved.